CRSP

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CRISPR Therapeutics AG revenue for the last quarter amounts to 889.00K USD, increased 47.67 % YoY.

CRISPR Therapeutics AG. EPS for the last quarter amounts to -1.17 USD, increased 15.84 % YoY.

CRISPR Therapeutics AG (CRSP) has 393 emplpoyees as of January 08 2026.

Today CRSP has the market capitalization of 5.37B USD.